News Press Contact: Kirsten Mabry | (617) 495-4157

Attivare, a startup advancing a portfolio of technologies developed at the Wyss Institute, John A. Paulson School of Engineering and Applied Sciences, Dana-Farber Cancer Institute, and Massachusetts General Hospital, has shown promising results in cancer clinical trials and is developing a malaria vaccine. Through decades of innovation and cross-disciplinary collaboration, the technology has the potential to fight cancer more effectively or prevent pathogen-related infections. 

For more than three decades, Greg Verdine has brought bold, innovative methods to solving some of medicine’s biggest challenges - from early-stage work backed by the Harvard Blavatnik Biomedical Accelerator to the launch of multiple startups.

Researchers at the Harvard John A. Paulson School of Engineering and Applied Sciences built a device called a pico-calorimeter that directly measures heat signals from small groups of living cells. The device could lead to advances in bacterial growth monitoring or antibiotic resistance testing.

Harvard University has expanded a research alliance agreement with Northpond Labs to fund translational research, accelerate commercialization, and advance breakthrough healthcare innovations across Harvard labs at the Wyss Institute, Harvard Medical School, John A. Paulson School of Engineering and Applied Sciences, and Faculty of Arts and Sciences.